디지털 치료 기기 시장 : 치료 영역별, 투여 방법별, 유통 채널별, 최종 사용자별 시장 예측(2026-2032년)

The Digital Therapeutic Devices Market is projected to grow by USD 29.62 billion at a CAGR of 19.10% by 2032.

Digital therapeutic devices are evidence-based software and connected medical solutions that deliver clinical interventions to prevent, manage, or treat disease. The category spans prescription digital therapeutics, software as a medical device, remote therapeutic monitoring tools, connected sensors, and app-enabled behavioral interventions for chronic disease, mental health, cardiometabolic care, respiratory conditions, neurological disorders, and rehabilitation.

Adoption is being driven by the global chronic disease burden, rising demand for mental health support, clinician shortages, aging populations, and the shift toward home-based and hybrid care. Verified indicators from the WHO, OECD, FDA, CMS, BfArM, NICE, MHRA, Health Canada, PMDA, TGA, and other public health authorities show that regulators and payers are increasingly treating clinically validated digital therapeutics as part of mainstream care delivery rather than optional wellness technology.

Transformative Shifts in the Digital Therapeutics Landscape

The digital therapeutic devices landscape is shifting from pilot programs to regulated, reimbursable, outcomes-oriented deployment. FDA-cleared software, Germany's DiGA pathway, France's early-access PECAN framework, the UK's NICE evidence standards, and software as a medical device guidance across major regulators demonstrate a stronger policy foundation for clinically validated digital health interventions.

Commercial success now depends on proof of clinical benefit, patient engagement, interoperability, cybersecurity, accessibility, and workflow integration. Providers are prioritizing solutions that reduce avoidable visits, support remote care, and generate measurable outcomes, while payers increasingly expect real-world evidence, health economics data, durable adherence, and transparent performance reporting across diverse patient populations.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is expanding the value of digital therapeutic devices by enabling adaptive interventions, risk stratification, adherence support, clinical decision support, symptom pattern recognition, and personalized behavior-change pathways. AI can help software respond to patient-reported outcomes, biomarker trends, and connected-device data in near real time, supporting more individualized care between clinical encounters.

The cumulative impact is significant but dependent on governance. Industry leaders must align AI-enabled digital therapeutics with FDA, Health Canada, MHRA, European, and international Good Machine Learning Practice principles, while addressing algorithmic bias, explainability, cybersecurity, data provenance, human oversight, model drift, and ongoing post-market monitoring.

Key Regional Insights

North America remains a leading region for digital therapeutic devices because of FDA software as a medical device guidance, CMS remote therapeutic monitoring codes, strong employer health programs, established clinical research networks, and growing provider interest in remote care. Europe is advancing through the EU Medical Device Regulation, Germany's DiGA reimbursement model, France's PECAN framework, and NICE evidence standards in the United Kingdom, creating a structured environment for clinically validated digital therapeutics and digital health technology assessment.

Asia-Pacific is scaling through Japan's PMDA review environment, South Korea's digital health pilots, China's large connected-health ecosystem, India's public digital health infrastructure, and Australia's TGA framework. Latin America is progressing through telehealth expansion in Brazil and Mexico, with demand shaped by access gaps and chronic disease management needs. The Middle East is supported by national digital health strategies, especially in GCC markets investing in connected hospitals and health system modernization. Africa shows long-term potential through mobile-first care models and public health digitization, although reimbursement, broadband access, clinical validation infrastructure, and procurement pathways remain uneven across countries.

Key Group Insights

The European Union is shaping digital therapeutic device adoption through harmonized medical device rules, data protection standards, electronic health initiatives, and cross-border digital health priorities. G7 markets continue to influence evidence expectations, reimbursement models, cybersecurity practices, AI governance, and post-market surveillance norms for regulated digital health solutions.

BRICS countries provide scale, diverse disease burdens, expanding smartphone access, and growing digital public infrastructure, making localization, affordability, language adaptation, and public-private care integration essential. ASEAN markets are mobile-first and benefit from expanding telehealth acceptance, urban hospital digitization, and government digital health strategies. GCC countries are investing in national health transformation programs, connected hospitals, and preventive care initiatives. NATO markets place additional emphasis on cyber resilience, secure health data exchange, trusted cloud infrastructure, and continuity of care across defense and civilian health systems.

Key Country Insights

The United States leads through FDA authorization pathways, CMS reimbursement mechanisms, employer adoption, academic clinical research, and strong digital health innovation. Canada is advancing through Health Canada oversight, provincial procurement, and virtual care integration, while Mexico and Brazil show demand linked to telehealth access, private health networks, chronic disease management, and uneven specialist availability across regions.

In Europe, the United Kingdom is guided by MHRA and NICE evidence standards, Germany by DiGA and BfArM processes, France by HAS and PECAN, and Italy and Spain by regional health system adoption and digital care modernization. Russia is emphasizing domestic digital health capacity and locally controlled health technology infrastructure. In Asia-Pacific, China, India, Japan, Australia, and South Korea are each scaling through different combinations of regulatory modernization, public digital infrastructure, connected-device adoption, telemedicine acceptance, clinical validation requirements, and increasing focus on cybersecurity and patient data protection.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated use cases where digital therapeutic devices can reduce care gaps, improve outcomes, or extend access to care. Early engagement with regulators, payers, clinicians, health technology assessment bodies, and patient groups is essential to align product claims, study design, evidence endpoints, data security, accessibility, and reimbursement strategy.

Organizations should build interoperable platforms using recognized standards such as HL7 FHIR, invest in real-world evidence, and implement AI governance from development through post-market surveillance. Commercial models should emphasize measurable outcomes, patient retention, clinician usability, health equity, localization, cybersecurity, and integration with existing electronic health record workflows.

Research Methodology

This executive summary is based on structured secondary research using verified public sources, including regulatory guidance, reimbursement policies, clinical trial registries, public health datasets, payer documentation, health technology assessment materials, and peer-reviewed literature. Key reference authorities include the FDA, CMS, WHO, OECD, ITU, EMA, BfArM, NICE, MHRA, Health Canada, PMDA, TGA, and national digital health agencies.

Insights were triangulated across regulatory, clinical, commercial, technology, and regional indicators to avoid reliance on unsupported claims. Emphasis was placed on validated market drivers, policy developments, adoption barriers, interoperability requirements, evidence standards, AI governance considerations, and regional access factors affecting digital therapeutic devices.

Conclusion

Digital therapeutic devices are moving into a more mature phase defined by clinical evidence, regulatory discipline, reimbursement readiness, interoperability, cybersecurity, and AI-enabled personalization. The strongest opportunities are emerging where software-based interventions solve measurable care gaps in chronic disease, behavioral health, rehabilitation, medication adherence, and remote monitoring.

Organizations that combine rigorous evidence generation, secure data architecture, clinician-friendly workflows, accessible patient experiences, and payer-aligned value propositions will be best positioned to lead. As global health systems demand scalable, equitable, and cost-effective care, digital therapeutics are becoming a critical layer of modern medical technology.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Digital Therapeutic Devices Market, by Therapeutic Area

• 7.1. Cardiovascular
  • 7.1.1. Heart Failure
  • 7.1.2. Hypertension
• 7.2. Diabetes Management
  • 7.2.1. Type 1 Diabetes
  • 7.2.2. Type 2 Diabetes
• 7.3. Mental Health
  • 7.3.1. Anxiety
  • 7.3.2. Depression
  • 7.3.3. Stress Management
• 7.4. Musculoskeletal
  • 7.4.1. Chronic Pain
  • 7.4.2. Physical Rehabilitation
• 7.5. Respiratory
  • 7.5.1. Asthma
  • 7.5.2. Copd

8. Digital Therapeutic Devices Market, by Delivery Mode

• 8.1. Mobile
• 8.2. VR AR
• 8.3. Wearable
• 8.4. Web

9. Digital Therapeutic Devices Market, by Distribution Channel

• 9.1. Offline
• 9.2. Online Platforms

10. Digital Therapeutic Devices Market, by End User

• 10.1. Home Settings
• 10.2. Hospitals And Clinics
• 10.3. Research Institutes

11. Digital Therapeutic Devices Market, by Region

• 11.1. Asia-Pacific
• 11.2. North America
• 11.3. Latin America
• 11.4. Europe
• 11.5. Middle East
• 11.6. Africa

12. Digital Therapeutic Devices Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Digital Therapeutic Devices Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Concentration Analysis, 2025
  • 14.1.1. Concentration Ratio (CR)
  • 14.1.2. Herfindahl Hirschman Index (HHI)
• 14.2. Recent Developments & Impact Analysis, 2025
• 14.3. Product Portfolio Analysis, 2025
• 14.4. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. 2Morrow, Inc.
• 15.2. Akili Interactive Labs, Inc.
• 15.3. Allurion Technologies, Inc.
• 15.4. AppliedVR, Inc.
• 15.5. Better Therapeutics, Inc.
• 15.6. Big Health Ltd.
• 15.7. Biofourmis, Inc.
• 15.8. Blue Note Therapeutics, Inc.
• 15.9. Canary Health, Inc.
• 15.10. Click Therapeutics, Inc.
• 15.11. CureApp, Inc.
• 15.12. DarioHealth Corp.
• 15.13. GAIA AG
• 15.14. Kaia Health Software GmbH
• 15.15. Lark Health, Inc.
• 15.16. MedRhythms, Inc.
• 15.17. Medtronic plc
• 15.18. Meru Health Inc.
• 15.19. MindMaze SA
• 15.20. Noom, Inc.
• 15.21. Omada Health, Inc.
• 15.22. Otsuka Holdings Co., Ltd.
• 15.23. Pear Therapeutics, Inc.
• 15.24. Propeller Health, Inc.
• 15.25. Teladoc Health, Inc.
• 15.26. Vida Health, Inc.
• 15.27. WellDoc, Inc.